← Back to Screener
Jasper Therapeutics, Inc. Common Stock (JSPR)
Price$0.53
Momentum ScoreF
Favorite Metrics
Price vs S&P 500 (26W)-68.83%
Price vs S&P 500 (4W)-15.86%
VGM Score9.70
Market Capitalization$23.21M
All Metrics
Book Value / Share (Quarterly)$0.12
P/TBV (Annual)2.04x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-2.46
Price vs S&P 500 (YTD)-65.63%
EPS (TTM)$-3.23
10-Day Avg Trading Volume0.28M
EPS Excl Extra (TTM)$-3.23
EPS (Annual)$-3.95
ROI (Annual)-1826.09%
Cash / Share (Quarterly)$0.51
ROA (Last FY)-211.86%
EBITD / Share (TTM)$-3.23
ROE (5Y Avg)-434.52%
Cash Flow / Share (Annual)$-2.76
P/B Ratio6.83x
P/B Ratio (Quarterly)7.21x
Net Income / Employee (Annual)$-3,445,500
Net Interest Coverage (TTM)-7.75x
ROA (TTM)-138.56%
EPS Incl Extra (Annual)$-3.95
Current Ratio (Annual)2.62x
Quick Ratio (Quarterly)1.62x
3-Month Avg Trading Volume0.42M
52-Week Price Return-85.40%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.85
52-Week High$7.19
EPS Excl Extra (Annual)$-3.95
26-Week Price Return-52.90%
Quick Ratio (Annual)2.22x
13-Week Price Return-39.49%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.26x
Enterprise Value$9.07M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$1.02
3-Month Return Std Dev94.00%
Net Income / Employee (TTM)$-2,533,400
ROE (Last FY)-1826.09%
Net Interest Coverage (Annual)-2.07x
EPS Basic Excl Extra (Annual)$-3.95
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-3.23
ROI (TTM)-523.04%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.95
Price vs S&P 500 (52W)-113.61%
Year-to-Date Return-54.70%
5-Day Price Return-8.19%
EPS Normalized (Annual)$-3.95
ROA (5Y Avg)-95.93%
Month-to-Date Return-11.43%
Cash Flow / Share (TTM)$-0.70
EBITD / Share (Annual)$-4.32
ROI (5Y Avg)-434.52%
EPS Basic Excl Extra (TTM)$-3.23
P/TBV (Quarterly)0.78x
P/B Ratio (Annual)12.34x
Book Value / Share (Annual)$0.15
Price vs S&P 500 (13W)-49.24%
Beta3.05x
Revenue / Share (TTM)$0.00
ROE (TTM)-523.04%
52-Week Low$0.62
mGradeF
vgmGradeF
Show chart for
Earnings Surprise History
Q1 26-0.04est. -0.50
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.00
4.00
3.93
3.93
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
JSPRJasper Therapeutics, Inc. Common Stock | — | — | F | $0.53 |
| AMGNAmgen Inc | C | C | C | $329.13 |
| GILDGilead Sciences Inc | C | B | C | $131.10 |
| ARGXargenx SE American Depositary Shares | D | A | C | $836.09 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $163.68 |
| BIIBBiogen Inc. Common Stock | B | D | B | $192.23 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.70 |
| MRNAModerna, Inc. Common Stock | C | B | B | $46.06 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $161.00 |
| EXELExelixis Inc | C | B | B | $50.28 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | B | $298.10 |
About
Jasper Therapeutics is a clinical-stage biotechnology company developing treatments based on hematopoietic stem cell transplantation. The company is developing safer conditioning agents and advanced stem cell engineering technologies to expand the therapeutic applications of stem cell transplantation and ex vivo gene therapy. By improving the safety and efficacy of these procedures, Jasper aims to enable broader patient access to stem cell-based treatments across multiple disease indications.